| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | August 17, 2023 |
| Accession Number: | 0001104659-23-092651 | ||||||
| Submission Type: | POS AM | ||||||
| |||||||
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
Company completes preferred stock conversion, implements reverse stock split, and regains Nasdaq compliance Company positioned for success with late-stage rare disease portfolio and multiple clinical milestones in 2023 DURHAM, N.C. and EXTON, Pa., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. ("Idera") (NASDAQ:IDRA), a clinical-stage biopharmaceutical company committed to transforming the care of people living with rare pulmonary and rheumatic diseases, today announced the Company has changed its name and symbol to Aceragen, Inc. ("Aceragen," the "Company," "we," "us," or "our") and "ACGN". Additionally, the Company's stockholders approved the conversion into common s
EXTON, Pa. and DURHAM, N.C., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. ("Idera," the "Company," "we," "us," or "our") (NASDAQ:IDRA) today reported its consolidated financial and operational results for the third quarter ended September 30, 2022. "We are pleased to have completed the merger of Idera and Aceragen at the end of the third quarter, better enabling us to deliver important therapies for people living with rare diseases," stated John Taylor, Idera's Chief Executive Officer. "Our resulting cash position is expected to provide runway into Q3 2023 and fund the advancement of our pipeline, including ACG-701 and ACG-801, through important anticipated 2023 clinical
Acquisition includes late-stage rare disease portfolio with anticipated 2023 clinical milestones and first potential product approval as early as late 2024 Conference call and webcast today at 5:00 p.m. ET EXTON, Pa. and DURHAM, N.C., Sept. 28, 2022 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. ("Idera," the "Company," "we," "us," or "our") (NASDAQ:IDRA) today announced it has completed the acquisition of Aceragen, Inc. ("Aceragen"), a privately-held biotechnology company addressing rare, orphan pulmonary and rheumatic diseases for which there are limited or no available treatments. The combined cash of the two companies is expected to provide runway into Q3 2023, funding the advanceme
Wedbush downgraded Idera Pharma from Outperform to Neutral and set a new price target of $1.00 from $8.00 previously
Barclays downgraded Idera Pharmaceuticals from Overweight to Equal-Weight and set a new price target of $2.00 from $10.00 previously
JMP Securities downgraded Idera Pharmaceuticals from Outperform to Market Perform
4 - Aceragen, Inc. (0000861838) (Issuer)
4 - Aceragen, Inc. (0000861838) (Issuer)
4 - Aceragen, Inc. (0000861838) (Issuer)
15-12G - Aceragen, Inc. (0000861838) (Filer)
EFFECT - Aceragen, Inc. (0000861838) (Filer)
EFFECT - Aceragen, Inc. (0000861838) (Filer)
SC 13D/A - Aceragen, Inc. (0000861838) (Subject)
SC 13D/A - Aceragen, Inc. (0000861838) (Subject)
SC 13D/A - Aceragen, Inc. (0000861838) (Subject)
Acquisition includes late-stage rare disease portfolio with anticipated 2023 clinical milestones and first potential product approval as early as late 2024 Conference call and webcast today at 5:00 p.m. ET EXTON, Pa. and DURHAM, N.C., Sept. 28, 2022 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. ("Idera," the "Company," "we," "us," or "our") (NASDAQ:IDRA) today announced it has completed the acquisition of Aceragen, Inc. ("Aceragen"), a privately-held biotechnology company addressing rare, orphan pulmonary and rheumatic diseases for which there are limited or no available treatments. The combined cash of the two companies is expected to provide runway into Q3 2023, funding the advanceme
EXTON, Pa., March 01, 2021 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera” or the “Company”) (Nasdaq: IDRA) today reported its financial and operational results for the fourth quarter and year ended December 31, 2020. “Tilsotolimod is the most advanced TLR-9 agonist therapy in development, and we are eagerly anticipating objective response rate and other important data from ILLUMINATE-301, our pivotal registration trial in anti-PD-1 refractory advanced melanoma, later this month,” stated Vincent Milano, Idera’s Chief Executive Officer. “I’m very proud of our team’s resiliency and tenacity as they work diligently toward that goal, as well as the ongoing work in ILLUMINATE-206,